AU2003272827B2 - Method for treating patients with massive blood loss - Google Patents

Method for treating patients with massive blood loss Download PDF

Info

Publication number
AU2003272827B2
AU2003272827B2 AU2003272827A AU2003272827A AU2003272827B2 AU 2003272827 B2 AU2003272827 B2 AU 2003272827B2 AU 2003272827 A AU2003272827 A AU 2003272827A AU 2003272827 A AU2003272827 A AU 2003272827A AU 2003272827 B2 AU2003272827 B2 AU 2003272827B2
Authority
AU
Australia
Prior art keywords
hemoglobin
solution
polymerized
molecular weight
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2003272827A
Other languages
English (en)
Other versions
AU2003272827A1 (en
Inventor
Richard E. Dewoskin
Marc D. Doubleday
Steven A. Gould
George A. Hides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northfield Laboratories Inc
Original Assignee
Northfield Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northfield Laboratories Inc filed Critical Northfield Laboratories Inc
Publication of AU2003272827A1 publication Critical patent/AU2003272827A1/en
Application granted granted Critical
Publication of AU2003272827B2 publication Critical patent/AU2003272827B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003272827A 2002-10-03 2003-10-03 Method for treating patients with massive blood loss Expired - Fee Related AU2003272827B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41593502P 2002-10-03 2002-10-03
US60/415,935 2002-10-03
PCT/US2003/031377 WO2004037279A1 (en) 2002-10-03 2003-10-03 Method for treating patients with massive blood loss

Publications (2)

Publication Number Publication Date
AU2003272827A1 AU2003272827A1 (en) 2004-05-13
AU2003272827B2 true AU2003272827B2 (en) 2009-03-19

Family

ID=32176456

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003272827A Expired - Fee Related AU2003272827B2 (en) 2002-10-03 2003-10-03 Method for treating patients with massive blood loss

Country Status (11)

Country Link
US (1) US7291592B2 (https=)
EP (1) EP1553968A4 (https=)
JP (1) JP2006502231A (https=)
CN (1) CN1703235A (https=)
AU (1) AU2003272827B2 (https=)
CA (1) CA2499459A1 (https=)
MX (1) MXPA05003340A (https=)
NO (1) NO20051390L (https=)
RU (1) RU2325924C2 (https=)
WO (1) WO2004037279A1 (https=)
ZA (1) ZA200502307B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049707A1 (en) * 2003-08-29 2005-03-03 Ferree Bret A. Cemented artificial disc replacements
EP1471821B1 (en) * 2002-01-15 2013-06-26 Board Of Regents, The University Of Texas System Compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures
US20070196810A1 (en) * 2006-01-24 2007-08-23 Northfield Laboratories Inc. Polymerized Hemoglobin Media and its Use in Isolation and Transplantation of Islet Cells
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
WO2008009634A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
RU2361608C1 (ru) * 2008-03-18 2009-07-20 Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Медбиофарм" Кровезаменитель с функцией переноса кислорода, фармацевтическая композиция (варианты)
RU2452519C1 (ru) * 2011-03-25 2012-06-10 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ компенсации глобулярного объема крови и иммуномодулирующего воздействия при трансплантации
CA3070172A1 (en) 2017-07-18 2019-01-24 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194590A (en) * 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5464814A (en) * 1986-06-20 1995-11-07 Northfield Laboratories, Inc. Acellular red blood cell substitute
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5955581A (en) * 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5854209A (en) 1995-03-23 1998-12-29 Biopure Corporation Method for oxygenating tissue having reduced red blood cell flow
US5084558A (en) * 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
US5691452A (en) * 1995-03-23 1997-11-25 Biopure Corporation Method for preserving a hemoglobin blood substitute
NZ305258A (en) * 1995-03-23 2000-10-27 Biopure Corp Stable polymerised haemoglobin blood-substitute to treat or prevent hypoxia resulting from blood loss
US6288027B1 (en) * 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5895810A (en) * 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
US6271351B1 (en) * 1995-03-23 2001-08-07 Biopure Corporation Method for preserving a hemoglobin blood substitute
US20020065211A1 (en) * 1995-03-23 2002-05-30 Biopure Corporation Increasing function of organs having reduced red blood cell flow
US6150507A (en) * 1995-03-23 2000-11-21 Biopure Corporation Method for producing a purified hemoglobin product
US5691453A (en) * 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
RU2203087C2 (ru) * 1996-03-28 2003-04-27 Нортфилд Лэборэтериз, Инк. Способ и устройство для получения бесклеточного заменителя эритроцитов
US5890852A (en) * 1998-03-17 1999-04-06 Emerson Electric Company Thread cutting die and method of manufacturing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOULD et al,The Journal of Trauma, 1997, Vol 43, pages 325-332. *
SEHGAL et al,Surgery, April 1984, Vol 95, No 4, pages 433-438. *

Also Published As

Publication number Publication date
MXPA05003340A (es) 2005-07-05
ZA200502307B (en) 2005-11-30
US20040067876A1 (en) 2004-04-08
EP1553968A4 (en) 2009-06-24
AU2003272827A1 (en) 2004-05-13
RU2325924C2 (ru) 2008-06-10
US7291592B2 (en) 2007-11-06
NO20051390L (no) 2005-05-30
CN1703235A (zh) 2005-11-30
EP1553968A1 (en) 2005-07-20
WO2004037279A1 (en) 2004-05-06
CA2499459A1 (en) 2004-05-06
JP2006502231A (ja) 2006-01-19
RU2005113240A (ru) 2005-12-10

Similar Documents

Publication Publication Date Title
US6552173B2 (en) Acellular red blood cell substitute
Vogel et al. Coronary constrictor effect of stroma-free hemoglobin solutions
JP5099951B2 (ja) 副作用が減少されたヘモグロビン組成物
Emmerson et al. Double blind trial of recombinant human erythropoietin in preterm infants.
AU622610B2 (en) Extra pure semi-synthetic blood substitute
NL194909C (nl) Werkwijze voor de bereiding van gepolymeriseerd hemoglobine en celvrij vervangingsmiddel voor rode bloedlichaampjes op basis daarvan.
Bjorkholm et al. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol
AU2003272827B2 (en) Method for treating patients with massive blood loss
JP2009537534A (ja) 急性失血の治療方法
Keipert et al. Pyridoxylated polyhemoglobin as a red cell substitute for resuscitation of lethal hemorrhagic shock in conscious rats
Dunlap et al. Resuscitation with diaspirin crosslinked hemoglobin in a pig model of hemorrhagic shock
Jahr et al. Hemoglobin‐based oxygen carriers: history, limits, brief summary of the state of the art, including clinical trials
Przybelski et al. A safety assessment of diaspirin cross-linked hemoglobin (DCLHb) in the treatment of hemorrhagic, hypovolemic shock
D'Ambra et al. Aprotinin, erythropoietin, and blood substitutes
Brooks Noncardiogenic pulmonary edema immediately following rapid protamine administration
US6046170A (en) Therapeutic use of hemoglobin to treat head injury
HK1084875A (en) Method for treating patients with massive blood loss
Shiono et al. Application of cryoprecipitate as a hematostatic glue
Bunyaratvej et al. Different Patterns of Intraerythrocytic Inclusion Body Distribution in the Two Types of Haemoglobin H Disease: An Ultrastructural Study
Ala Transfusion of Red Cells
AU722301B2 (en) Use of hemoglobin to prevent sepsis or treat systemic inflammatory response syndrome
Rao Blood Conservation-How Practical?
Mackenzie Hemoglobin-based oxygen-carrying solutions and hemorrhagic shock
Spahn et al. Augmented Acute Normovolemic Hemodilution
CONLEY et al. Hemolytic reactions associated with surgical procedures

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee